Related Experiment Video
Updated: May 17, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
KRAS mutations in lung cancer
Niki Karachaliou1, Clara Mayo, Carlota Costa
1Pangaea Biotech, Dexeus University Institute, Barcelona, Spain.
Clinical Lung Cancer
|November 6, 2012
Summary
KRAS mutations in non-small-cell lung cancer (NSCLC) predict poor response to chemotherapy and EGFR inhibitors. New therapies targeting KRAS-mutant NSCLC are needed.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) mutations and copy number increase predict response to EGFR tyrosine kinase inhibitors (TKI) in non-small-cell lung cancer (NSCLC).
- KRAS mutations are common in lung adenocarcinomas and are mutually exclusive with EGFR mutations.
- KRAS mutations have significant clinical implications, affecting treatment response and prognosis in NSCLC.
Purpose of the Study:
- To review the clinical and pathological characteristics of NSCLC patients with KRAS mutations.
- To explore the predictive and prognostic influence of KRAS mutations in NSCLC.
- To provide an overview of targeting strategies for KRAS-mutant NSCLC, including synthetic lethality.
Main Methods:
- Literature review of studies on KRAS mutations in NSCLC.
- Analysis of clinical and pathological data associated with KRAS mutations.
- Summary of current and emerging therapeutic approaches for KRAS-mutant NSCLC.
Main Results:
- KRAS mutations are associated with a lack of benefit from adjuvant chemotherapy in NSCLC patients.
- Patients with KRAS-mutant NSCLC do not respond to EGFR inhibitors.
- KRAS mutation status is a critical determinant of treatment efficacy and patient outcomes.
Conclusions:
- There is a significant need for targeted therapies for NSCLC patients with KRAS mutations.
- Understanding KRAS mutation status is crucial for personalized treatment strategies in NSCLC.
- Synthetic lethal approaches and novel drug development hold promise for treating KRAS-mutant NSCLC.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...